Key Takeaway: Precision BioSciences reported its second quarter 2024 financial results, highlighting progress in its wholly owned programs PBGENE-HBV for Chronic Hepatitis B and PBGENE-PMM for mitochondrial disease. Both programs are on schedule for IND and CTA submissions in 2024 and 2025, respectively. The company also expanded its Hepatitis Scientific Advisory Board with renowned clinical investigators.
Price reaction · baseline $9.53 (2024-07-31 close) · hit pre-market · clean, no other DTIL news in the window
day 0 close
+0.4%
day 1
-2.2%
day 3 · peak
-8.7%
Market Sentiment Analysis
POSITIVE FACTORS
Programs PBGENE-HBV and PBGENE-PMM are on track for submissions.
Expansion of the Hepatitis Scientific Advisory Board with top clinical experts.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer
Full Press Release Details
– Wholly owned programs PBGENE-HBV for Chronic Hepatitis B virus and PBGENE-PMM for m.3243 mitochondrial disease on track for IND and/or CTA submissions in 2024 and 2025, respectively – Expanded Hepatitis Scientific Advisory Board with addition of world-class clinical investigators Mark Sulkowski ,
Frequently Asked Questions
What programs are reported by Precision BioSciences?
Precision BioSciences reported on PBGENE-HBV for Chronic Hepatitis B and PBGENE-PMM for mitochondrial disease.
When are the IND and CTA submissions planned?
The IND submission for PBGENE-HBV is planned for 2024, and for PBGENE-PMM in 2025.
Who joined the Hepatitis Scientific Advisory Board?
Mark Sulkowski and other world-class clinical investigators joined the board.